Physician

Adarsh Daswani, M.D.

According to 2025 Medicare claims, Adarsh Daswani, M.D. (NPI: 1598861882) practices nephrology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. This provider's primary affiliated billing organization is MOTI S DASWANI MD INC (NPI: 1255357315; TIN: 95-3496295) and primary practice location at 90723-4633.

Daswani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 128 traditional Medicare patients, billed 728 HCPCS/CPT codes, and received $98,237 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 942 prescription claims across 190 beneficiaries totaling $221,732 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). DME data shows 142 claims. Open Payments data shows 2 records totaling $121. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $238,628 to $98,237. Similarly, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $583,344 to $221,732. In contrast, DME billing represents a smaller volume and changed little.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	275	1,756	$238,628
2016	257	1,654	$230,692
2017	231	1,551	$235,074
2018	226	1,411	$220,103
2019	209	1,226	$184,774
2020	183	1,166	$182,862
2021	137	900	$171,041
2022	122	769	$135,778
2023	130	826	$126,165
2024	128	728	$98,237

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	288	2,639	$583,344
2016	301	2,655	$627,131
2017	265	2,338	$591,189
2018	265	1,813	$262,894
2019	276	1,628	$216,838
2020	222	1,392	$191,636
2021	208	1,119	$217,584
2022	177	847	$197,757
2023	181	902	$236,165
2024	190	942	$221,732

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	155	$11,587
2016	N/R	264	$18,001
2017	N/R	367	$24,074
2018	N/R	271	$17,002
2019	N/R	177	$5,365
2020	N/R	90	$2,827
2021	N/R	68	$2,618
2022	N/R	139	$3,681
2023	N/R	198	$4,760
2024	N/R	142	$3,577

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	36	132	$294
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	38	46	$142
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	44	90	$77
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	45	194	$65
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	39	73	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	29	915	$66,298
Farxiga	Dapagliflozin Propanediol	20	1,680	$29,150
Sevelamer Carbonate	Sevelamer Carbonate	73	3,778	$17,423
Prosol	Parenteral Amino Acid 20% No.1	71	496	$12,789
Lokelma	Sodium Zirconium Cyclosilicate	16	584	$10,487

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	13	$1,299
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	48	$838
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	33	$699
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	19	$402
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	29	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$121	Bard Peripheral Vascular, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adarsh Daswani, M.D.?

Tedicare shows public-source Medicare data for Adarsh Daswani, M.D. (NPI 1598861882), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adarsh Daswani, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adarsh Daswani, M.D.?

Adarsh Daswani, M.D. is linked to MOTI S DASWANI MD INC (billing NPI 1255357315) in the available physician profile data.

Does Adarsh Daswani, M.D. have Open Payments data?

Adarsh Daswani, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.